AtriCure, Inc.

AtriCure, Inc. is dedicated to providing innovative technologies for the treatment of Afib and related conditions, impacting the lives of over 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons globally utilize AtriCure technologies, including the Isolator® Synergy™ Ablation System, the first FDA-approved device for persistent Afib treatment, and the AtriClip® Left Atrial Appendage Exclusion System, a leading LAA management solution. AtriCure's commitment extends to offering advanced solutions like Hybrid AF™ Therapy, a minimally invasive procedure for long-standing persistent Afib patients, and the cryoICE cryoSPHERE® probe for temporary peripheral nerve ablation, providing pain relief in cardiac and thoracic procedures.

Located primarily at 7555 Innovation Way, Mason, Ohio 45040, US, with additional locations including 130 Cheshire Ln, Suite 250, Minnetonka, Minnesota 55305, US; 3875 Hopyard Rd, Unit 160, Pleasanton, California 94588, US; De Entree, 260, Amsterdam, North Holland 1101, NL; and 3A Chater Road, Level 16, The Hong Kong Club Building, Central, HK, AtriCure continues to expand its reach and impact in the medical field. AtriCure’s comprehensive approach to Afib treatment and pain management establishes it as a key player in medical equipment manufacturing, delivering state-of-the-art solutions to healthcare professionals worldwide. The company aims to enhance patient outcomes through continuous innovation and a dedication to improving the quality of life for those affected by cardiac conditions and post-surgical pain.

AtriCure is constantly evolving and is focused on further innovations to address the needs of patients and healthcare providers. AtriCure’s mission is to remain at the forefront of medical technology, offering advanced and effective treatments. We invite the manager of AtriCure to create a customized and exclusive company showcase and product listing on our platform to further highlight its offerings and connect with a broader audience.